MDG1.DE stock opened sharply lower pre-market on 05 Mar 2026 after a heavy intraday sell-off that pushed the share price to EUR 0.13. The immediate fact is the drop of -27.64% on elevated volume of 189,470 shares, well above the 50-day average. Traders seeking an oversold bounce should note the wide intraday range (EUR 0.08–0.16) and the stock’s long-term averages at EUR 1.41 (50-day) and EUR 1.66 (200-day). This report frames a measured short-term rebound strategy for Medigene AG (MDG1.DE) on XETRA in Germany

MDG1.DE stock: price action and immediate catalysts

MDG1.DE stock fell to EUR 0.13 after opening at EUR 0.16, with a one-day low at EUR 0.08. The drop reflects a sharp volume spike to 189,470 versus average 43,152, which signals forced selling and short-term liquidity stress. The nearest technical support is the year low EUR 0.11, while the year high stands at EUR 4.16, showing the stock’s historic volatility.

MDG1.DE stock: fundamentals and valuation snapshot

Medigene AG reports EPS of -1.21 and a negative PE ratio of -0.11, reflecting losses. The market cap is roughly EUR 1,967,470, with 14,737,600 shares outstanding. Key ratios show a PB of 0.08 and price-to-sales of 0.33, which signal a depressed valuation versus peers in Healthcare where average PE is 30.36. The company retains EUR 1.36 cash per share and a current ratio of 2.53, supporting short-term solvency.

MDG1.DE stock: technical oversold bounce setup

Price far below its 50-day and 200-day averages creates an oversold condition on XETRA. The intraday range and volume spike often precede short squeezes in microcap biotech names. For a bounce trade we watch a first resistance band at EUR 0.20 and a stronger zone at EUR 0.40. Risk control: stop-loss below EUR 0.10 and position size under 1% of portfolio value given high volatility.

MDG1.DE stock: Meyka AI grade and valuation context

Meyka AI rates MDG1.DE with a score out of 100: 61.97 / B — HOLD. This grade factors S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The proprietary grade balances depressed market valuation metrics with decent cash per share and research assets; it is not a recommendation and not financial advice.

MDG1.DE stock: risks, catalysts, and sector context

Primary risk is continued cash burn and negative earnings; EPS stands at -1.21 and operating cash flow per share is -1.23. Catalysts include clinical updates, partner news from 2seventy bio, and any cash‑raising clarity. Healthcare sector performance is modest; average net margin across the sector is negative, so biotech-specific binary events will drive MDG1.DE stock more than macro trends.

MDG1.DE stock: practical trading plan and watchlist levels

For an oversold bounce tactic consider scaling in below EUR 0.15 and trimming into strength at EUR 0.20 and EUR 0.40. Use tight stops and small sizing; implied short-term target is EUR 0.25 for an initial exit. Track average volume and news flow on Medigene’s website and LinkedIn for clinical updates; see company pages at Medigene and LinkedIn. Also monitor our Meyka page for live updates: https://meyka.ai/stocks/MDG1.DE

Final Thoughts

Key takeaways: MDG1.DE stock trades at EUR 0.13 pre-market on XETRA and shows classic oversold signals after a -27.64% drop on heavy volume. Fundamentals show negative EPS (-1.21) and low market cap (EUR 1,967,470), but decent cash per share (EUR 1.36) supports a short-term tactical bounce. Meyka AI’s forecast model projects a near-term target of EUR 0.25, which implies an upside of +87.30% versus the current price of EUR 0.1335; forecasts are model-based projections and not guarantees. Our stock grade is 61.97 / B — HOLD, reflecting mixed fundamentals and binary clinical risk. Traders using an oversold bounce strategy should size small, set a stop below EUR 0.10, and take partial profits at EUR 0.20–0.25 while watching clinical news and volume as trade triggers. Meyka AI provides this AI-powered market analysis platform insight to help structure the trade view, but this should not substitute for independent research.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.